245 related articles for article (PubMed ID: 35057807)
1. Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk.
Böhm M; Schumacher H; Werner C; Teo KK; Lonn EM; Mahfoud F; Speer T; Mancia G; Redon J; Schmieder RE; Sliwa K; Marx N; Weber MA; Laufs U; Williams B; Yusuf S; Mann JFE
Cardiovasc Diabetol; 2022 Jan; 21(1):12. PubMed ID: 35057807
[TBL] [Abstract][Full Text] [Related]
2. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes.
Wada T; Haneda M; Furuichi K; Babazono T; Yokoyama H; Iseki K; Araki S; Ninomiya T; Hara S; Suzuki Y; Iwano M; Kusano E; Moriya T; Satoh H; Nakamura H; Shimizu M; Toyama T; Hara A; Makino H;
Clin Exp Nephrol; 2014 Aug; 18(4):613-20. PubMed ID: 24132561
[TBL] [Abstract][Full Text] [Related]
4. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
[TBL] [Abstract][Full Text] [Related]
5. Diabetes, gender and deterioration in estimated glomerular filtration rate in patients with chronic heart failure: Ten-year prospective cohort study.
Kearney J; Drozd M; Walker AM; Slater TA; Straw S; Gierula J; Paton M; Lowry J; Cole C; Witte KK; Cubbon RM; Kearney MT
Diab Vasc Dis Res; 2021; 18(1):1479164120984433. PubMed ID: 33588611
[TBL] [Abstract][Full Text] [Related]
6. Risk of Rapid Kidney Function Decline, All-Cause Mortality, and Major Cardiovascular Events in Nonalbuminuric Chronic Kidney Disease in Type 2 Diabetes.
Buyadaa O; Magliano DJ; Salim A; Koye DN; Shaw JE
Diabetes Care; 2020 Jan; 43(1):122-129. PubMed ID: 31796570
[TBL] [Abstract][Full Text] [Related]
7. Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study.
Koye DN; Magliano DJ; Reid CM; Jepson C; Feldman HI; Herman WH; Shaw JE
Am J Kidney Dis; 2018 Nov; 72(5):653-661. PubMed ID: 29784612
[TBL] [Abstract][Full Text] [Related]
8. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.
Perkovic V; Toto R; Cooper ME; Mann JFE; Rosenstock J; McGuire DK; Kahn SE; Marx N; Alexander JH; Zinman B; Pfarr E; Schnaidt S; Meinicke T; von Eynatten M; George JT; Johansen OE; Wanner C;
Diabetes Care; 2020 Aug; 43(8):1803-1812. PubMed ID: 32444457
[TBL] [Abstract][Full Text] [Related]
9. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
10. Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
Rotbain Curovic V; Theilade S; Winther SA; Tofte N; Eugen-Olsen J; Persson F; Hansen TW; Jeppesen J; Rossing P
Diabetes Care; 2019 Jun; 42(6):1112-1119. PubMed ID: 30885954
[TBL] [Abstract][Full Text] [Related]
11. Multifactorial intervention with nurse practitioners does not change cardiovascular outcomes in patients with chronic kidney disease.
van Zuilen AD; Bots ML; Dulger A; van der Tweel I; van Buren M; Ten Dam MA; Kaasjager KA; Ligtenberg G; Sijpkens YW; Sluiter HE; van de Ven PJ; Vervoort G; Vleming LJ; Blankestijn PJ; Wetzels JF
Kidney Int; 2012 Sep; 82(6):710-7. PubMed ID: 22739979
[TBL] [Abstract][Full Text] [Related]
12. Diabetes mellitus as a cause or comorbidity of chronic kidney disease and its outcomes: the Gonryo study.
Iwai T; Miyazaki M; Yamada G; Nakayama M; Yamamoto T; Satoh M; Sato H; Ito S
Clin Exp Nephrol; 2018 Apr; 22(2):328-336. PubMed ID: 28752289
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V
Circulation; 2018 Oct; 138(15):1537-1550. PubMed ID: 29941478
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease.
Sasso FC; Pafundi PC; Simeon V; De Nicola L; Chiodini P; Galiero R; Rinaldi L; Nevola R; Salvatore T; Sardu C; Marfella R; Adinolfi LE; Minutolo R;
Cardiovasc Diabetol; 2021 Jul; 20(1):145. PubMed ID: 34271948
[TBL] [Abstract][Full Text] [Related]
15. Variability in estimated glomerular filtration rate values is a risk factor in chronic kidney disease progression among patients with diabetes.
Tseng CL; Lafrance JP; Lu SE; Soroka O; Miller DR; Maney M; Pogach LM
BMC Nephrol; 2015 Mar; 16():34. PubMed ID: 25885708
[TBL] [Abstract][Full Text] [Related]
16. Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results.
Weir MR; McCullough PA; Buse JB; Anderson J
Am J Nephrol; 2020; 51(4):276-288. PubMed ID: 32172239
[TBL] [Abstract][Full Text] [Related]
17. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B;
Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733
[TBL] [Abstract][Full Text] [Related]
18. Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk.
Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Emrich I; Mancia G; Redon J; Schmieder RE; Sliwa K; Lehrke M; Marx N; Weber MA; Williams B; Yusuf S; Mann JFE
J Hypertens; 2021 Apr; 39(4):766-774. PubMed ID: 33560052
[TBL] [Abstract][Full Text] [Related]
19. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study).
Goicoechea M; de Vinuesa SG; Quiroga B; Verde E; Bernis C; Morales E; Fernández-Juárez G; de Sequera P; Verdalles U; Delgado R; Torres A; Arroyo D; Abad S; Ortiz A; Luño J
Cardiovasc Drugs Ther; 2018 Jun; 32(3):255-263. PubMed ID: 29943364
[TBL] [Abstract][Full Text] [Related]
20. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT
Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
